Interim results from OPTIMIZE-1 phase II study show >50% ORR in pancreatic cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Interim results from the ongoing OPTIMIZE-1 phase II study of mitazalimab in combination with chemotherapy, mFOLFIRINOX, in first line metastatic pancreatic cancer demonstrate an objective response rate of 52% in 23 evaluable patients, as per the Response Evaluation Criteria in Solid Tumors. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login